- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Peptide firm Diatide scores financing
Peptide-based radiopharmaceutical Diatide of Londonderry, NH, raised $11.8 million last month through a placement of preferred stock to existing investors. The preferred stock is convertible into 1.2 million shares of Diatide common stock. Diatide
Peptide-based radiopharmaceutical Diatide of Londonderry, NH, raised $11.8 million last month through a placement of preferred stock to existing investors. The preferred stock is convertible into 1.2 million shares of Diatide common stock. Diatide executives said the funds would be used for intermediate-term financing needs, to move its late-stage products toward commercialization, and to increase R&D in the area of therapeutic agents.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
MRI-Based AI Model Shows Promise in Predicting Lymph Node Metastasis with Breast Cancer
April 15th 2024For the prediction of axillary lymph node metastasis in patients with breast cancer, an MRI-based, 4D convolutional neural network model demonstrated an AUC of 87 percent and sensitivity of 89 percent, according to new research.
